Generic Name(s): Ado-Trastuzumab Emtansine
Kadcyla™ is the trade name for ado-trastuzumab emtansine. In some cases, health care professionals may use the trade name Kadcyla™ when referring to the generic drug name ado-trastuzumab emtansine.

Drug type: Kadcyla™ is an Anti-HER2 monoclonal antibody combined with a microtubular inhibitor. (For more detail, see "How this drug works" section below).

What this drug is used for:
Kadcyla™ is used as a single agent to treat HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
  • Received prior therapy for metastatic disease, or
  • Developed disease recurrence during or within 6 months of completely adjuvant therapy

Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful

How this drug is given:
  • Kadcyla™ is given through an infusion into a vein (intravenous, IV)

The amount of Kadcyla™ that you will receive depends on many factors, including your weight, your general health or other health problems, and the type of cancer or condition being treated. Your doctor will determine your dose and schedule.

Kadcyla™ Side effects:
Important things to remember about the side effects of Kadcyla™:
  • Most people will not experience all of the Kadcyla™ side effects listed.
  • Kadcyla™ side effects are often predictable in terms of their onset, duration, and severity.
  • Kadcyla™ side effects will improve after therapy is complete.
  • Kadcyla™ side effects may be quite manageable. There may be options to minimize or prevent the side effects of Kadcyla™.

The following side effects are common (occurring in greater than 30%) for patients taking Kadcyla™ :
  • Increased liver enzymes (AST, ALT)
  • Decreased platelet count
  • Decreased red blood cells
  • Nausea
  • Decreased white blood cells
  • Fatigue
  • Musculoskeletal pain (joint and muscle pain)
  • Decreased potassium